Development of a Bead-Based Multiplex Assay for the Analysis of the Serological Response against the Six Pathogens HAV, HBV, HCV, CMV, T. gondii, and H. pylori by Filomena, Angela et al.
Article
Development of a Bead-Based Multiplex Assay for
the Analysis of the Serological Response against the
Six Pathogens HAV, HBV, HCV, CMV, T. gondii,
and H. pylori
Angela Filomena 1 ID , Frank Pessler 2,3,4, Manas K. Akmatov 2,3,4 ID , Gérard Krause 2,3,5,
Darragh Duffy 6,7,8, Barbara Gärtner 9, Markus Gerhard 10 ID , Matthew L. Albert 6,7,8,
Thomas O. Joos 1 and Nicole Schneiderhan-Marra 1,*
1 NMI Natural and Medical Sciences Institute at the University of Tuebingen, 72770 Reutlingen, Germany;
angela.filomena@gmx.de (A.F.); thomas.joos@nmi.de (T.O.J.)
2 TWINCORE, Centre for Experimental and Clinical Infection Research, 30625 Hanover, Germany;
pessler.frank@mh-hannover.de (F.P.); manas.akmatov@helmholtz-hzi.de (M.K.A.);
gerard.krause@helmholtz-hzi.de (G.K.)
3 Helmholtz Centre for Infection Research, 38124 Brunswick, Germany
4 Centre for Individualized Infection Medicine, 30625 Hanover, Germany
5 Translational Infrastructure Epidemiology, German Centre for Infection Research (DZIF),
30625 Hanover, Germany
6 Immunobiology of Dendritic Cells, Institute Pasteur, 75015 Paris, France;
darragh.duffy@pasteur.fr (D.D.); matthew.albert@pasteur.fr (M.L.A.)
7 Inserm U1223, Institute Pasteur, 75015 Paris, France
8 Centre for Translational Research, Institute Pasteur, 75015 Paris, France
9 Institut für Mikrobiologie und Hygiene, 66421 Homburg/Saar, Germany; barbara.gaertner@uks.eu
10 TUM Technical University of Munich, 80333 Munich, Germany; markus.gerhard@tum.de
* Correspondence: nicole.schneiderhan@nmi.de; Tel.: +49-(0)7121-51-530-815
Academic Editors: Xiaobo Yu and Joshua LaBaer
Received: 31 August 2017; Accepted: 26 October 2017; Published: 30 October 2017
Abstract: The spread of infectious diseases and vaccination history are common subjects of
epidemiological and immunological research studies. Multiplexed serological assays are useful
tools for assessing both current and previous infections as well as vaccination efficacy. We developed
a serological multi-pathogen assay for hepatitis A, B and C virus, cytomegalovirus (CMV), Toxoplasma
gondii, and Helicobacter pylori using a bead-based multiplex assay format. The multi-pathogen
assay consisting of 15 antigens was utilized for the analysis of the serological response in elderly
individuals of an influenza vaccination study (n = 34). The technical assay validation revealed a mean
intra-assay precision of coefficient of variation (CV) = 3.2 ± 1.5% and a mean inter-assay precision
of CV = 8.2 ± 5.3% across all 15 antigens and all tested samples, indicating a robust test system.
Furthermore, the assay shows high sensitivities (ranging between 94% and 100%) and specificities
(ranging between 93% and 100%) for the different pathogens. The highest seroprevalence rates in
our cohort were observed for hepatitis A virus (HAV; 73.5%), followed by CMV (70.6%), T. gondii
(67.6%) and H. pylori (32.4%). Seroprevalences for hepatitis B virus (HBV, 8.8%) and hepatitis C virus
(HCV, 0%) were low. The seroprevalences observed in our study were similar to those from other
population-based studies in Germany. In summary, we conclude that our multiplex serological assay
represents a suitable tool for epidemiological studies.
Keywords: multiplex; serotest; multi-pathogen assay; seroprevalence; hepatitis; cytomegalovirus
(CMV); Toxoplasma gondii; Helicobacter pylori
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1. Introduction
The spread of infectious diseases and vaccination history are common subjects of epidemiological
and immunological research studies. Chronic or latent pathogen infections can be a strong risk factor
for several pathologies such as cancer [1,2], rheumatic diseases [3,4] and other chronic illnesses [5,6].
Furthermore, infections of pregnant women, with for example the TORCH pathogens (Toxoplasma
gondii, syphilis, varicella-zoster, parvovirus B19, Rubella, CMV, and Herpes), are known to cause
severe outcomes to their fetus and new born infants [7].
Commercially available screening assays, e.g., enzyme-linked immunosorbent assays (ELISA),
can test only for antibodies against one pathogen in a sample. Therefore, a multitude of different
ELISAs have to be used to perform epidemiological studies on seroprevalences of different pathogens,
which is associated with higher costs and logistics. In contrast, multiplex technologies allow the
analysis of different parameters in one sample. Thus, a multiplexed serological assay may be a useful
tool for assessing both current and previous infections as well as vaccination efficacy and/or history.
The Luminex xMAP technology (Luminex Corp., Austin, TX, USA) offers the possibility to differentiate
up to 500 different color-coded paramagnetic bead populations, which can be measured by the
FLEXMAP 3D analyzer (Luminex Corp.). By immobilizing one antigen on a certain bead population
and mixing different bead populations after antigen immobilization, multiplex serology becomes
possible. It has been shown before that antibodies towards multiple pathogens can be detected
simultaneously in a multiplex assay setup using the Luminex xMAP technology [8,9].
Here, we present the development and validation of a bead-based multi-pathogen serological
assay for hepatitis A virus (HAV), hepatitis B virus (HBV), hepatitis C virus (HCV), CMV, T. gondii,
and Helicobacter pylori. The assay was initially developed for HCV not only to differentiate negative
and positive antibody response but also to discriminate acute from chronic HCV infection. Due to the
fact that other pathogens, e.g., HAV, HBV, CMV, T. gondii, and H. pylori, can cause the same more or
less unspecific symptoms as an acute HCV infection, the assay was expanded to these other pathogens.
We used the developed multi-pathogen assay to assess the seroprevalences of the above mentioned
infections as well as HAV and HBV vaccination history in an influenza vaccination study cohort.
2. Materials and Methods
2.1. Antigens
In total, 15 antigens deriving from six different pathogens (HAV, HBV, HCV, CMV, T. gondii,
and H. pylori) were used in the serological bead-based multi-pathogen assay. For HAV four antigens
were used: a formalin inactivated full virus preparation and three purified structural proteins (VP4-VP2,
VP3, and VP1) recombinantly expressed in Escherichia coli. For HBV, three antigens were used: purified
hepatitis B core antigen (HBcAg) recombinantly expressed in E. coli and two hepatitis B surface antigen
(HBsAg) preparations (HBsAg ad and HBsAg ay) highly purified from human plasma. For HCV five
antigens were used: four purified proteins (Core g4a, Core g1b, NS3 g1a, and NS3 g1b) recombinantly
expressed in E. coli and a customized peptide (c22 g1a). For CMV, T. gondii, and H. pylori, one antigen
was used for each pathogen: for CMV, a whole cell lysate of strain AD169, for T. gondii, a sonicate of
whole tachyzoites (RH strain), and for H. pylori, a soluble protein extract of strain 49503.
2.2. Human Sera
For the development of the serological bead-based multi-pathogen assay, a variety of samples
positive and negative for the six pathogens was necessary. Fifteen samples negative for anti-HAV
IgG, anti-HBcAg IgG, and anti-HBsAg IgG, 15 samples positive for anti-HBsAg IgG, and anti-HAV
IgG, 15 samples positive for anti-HBcAg IgG and anti-HBsAg IgG, 10 samples negative for anti-CMV
IgG, 20 samples positive for anti-CMV IgG, 10 samples negative for anti-Toxo IgG, and 10 samples
positive for anti-Toxo IgG were purchased from Biomex (Heidelberg, Germany). Anti-HAV IgG were
determined using the ARCHITECT i1000SR Anti-HAV Ab IgG Reagent Kit (Abbott Laboratories,
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Abbott Park, IL, USA), anti-HBcAg IgG by ARCHITECT i1000SR Anti-HBc II Ab IgG Reagent Kit
(Abbott Laboratories, Abbott Park, IL, USA), anti-HBsAg IgG by ARCHITECT i1000SR Anti-HBs
Ab IgG Reagent Kit (Abbott Laboratories), anti-CMV IgG by ARCHITECT i1000SR Anti-CMV IgG
Reagent Kit (Abbott Laboratories) and anti-Toxo IgG by ARCHITECT i1000SR Anti-Toxo IgG Reagent
Kit (Abbott Laboratories).
Samples positive (n = 141) and negative (n = 87) for HCV were received during the European
Commission FP7 project SPHINX. HCV was identified by positive HCV-RNA (reverse-transcriptase
polymerase chain reaction; RT-PCR). Protocols were reviewed and approved by local ethical committees
and conform to the ethical guidelines of the 1975 Declaration of Helsinki. The healthy control sera
confirmed to be negative for HCV were obtained from blood banks in Cairo (n = 26) and from the
Etablissement Français du Sang (French National Blood Service) France (n = 61). Another 30 samples
negative for HCV antibodies were purchased from Seralab (Sera Laboratories International Ltd.,
West Sussex, United Kingdom). Furthermore, 20 samples of patients acutely infected with HAV
(positive anti-HAV IgM Ab) and another 20 samples of patients acutely infected with HBV (positive by
Corzyme M; ribosomal DNA; Abbott Laboratories (Abbott Park, IL, USA) and Auszyme Monoclonal;
third-generation enzyme immunoassay; Abbott Laboratories) were also obtained during the SPHINX
project. The samples are described elsewhere [10]. In addition, a set of samples positive (n = 92)
or negative (n = 142) for anti-HBc IgG (ARCHITECT i1000SR Anti-HBc II Ab IgG Reagent Kit,
Abbott Laboratories) was obtained from Barbara Gärtner (Institut für Mikrobiologie und Hygiene,
Homburg/Saar) and fall under the central ethical statement 2003. The Technical University of Munich
(TUM) provided samples positive (n = 414) and negative (n = 338) for H. pylori. The diagnosis as
positive or negative for a H. pylori infection was determined by Warthin–Starry silver stain. The study
was approved by the ethics committee of the TUM (20 May 2009, no. 2453/09). The study cohort is
described elsewhere [11].
The developed multi-pathogen assay was used to analyze the serological response in a pilot
influenza vaccination study cohort consisting of 162 samples from a total number of 34 study
participants aged 65–80 years (median 70 years) recruited from the general population. The study
cohort is described elsewhere [12]. The samples of study day 0 were screened with a commercial
CMV ELISA (CMV-IgG-ELISA PKS, medac GmbH, Wedel, Germany). The study was carried out with
the approval of the ethics committee of Hanover Medical School (file no. 6775) and in accordance
with national law and the Helsinki Declaration (in its current, revised form: 64th WMA General
Assembly, Fortaleza, Brazil, October 2013). Written informed consent was obtained from all study
participants before study assessments were begun. The study was registered on ClinicalTrials.gov
database (no. NCT02362919) prior to starting.
2.3. Antigen Immobilization
The immobilization of proteins was performed as described previously [13]. Briefly, a magnetic
particle processor (KingFisher 96, Thermo Scientific, Schwerte, Germany) was used to
immobilize the proteins on paramagnetic carboxylated beads (MagPlex microspheres, Luminex
Corp., Austin, TX, USA). The proteins were covalently immobilized onto the beads using
1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC)/sulfo-N-hydroxysuccinimide (sulfo-NHS)
chemistry and a coupling concentration of 50 µg/mL per protein. After immobilization, beads were
stored at 4◦C until further use.
The HCV peptide c22 g1a was immobilized to a carrier protein using an amine-to-sulfhydryl
crosslinker. First, the carrier protein bovine serum albumin (BSA; coupling concentration:
100 µg/mL) was immobilized on beads using EDC/sulfo-NHS chemistry as described previously [13].
These BSA-beads were activated for 1 h at room temperature (RT) with 100 µL sulfosuccinimidyl
4-(N-maleimidophenyl)butyrate (sulfo-SMPB) solution (1.5 mg/mL) + 100 µL PBS + 0.01%
(v/v) Triton X-100. The cysteine containing peptide was reduced with one molar equivalent
tris(2-carboxyethyl)phosphine (TCEP). Therefore, 50 µL cysteine peptide solution (1 mM)
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was incubated with 50 µL TCEP solution (1 mM in PBS) for 20 min at RT. At the end of the reaction,
150 µL PBS + 0.0125% (v/v) Triton X-100 was added. Activated beads were washed twice with 500 µL
PBS + 0.005% (v/v) Triton X-100. The reduced peptide was incubated with the activated beads for 1
h at room temperature (RT). Beads were washed twice with 500 µL PBS + 0.005% (v/v) Triton X-100,
resuspended in 300 µL CBS (PBS + 1% (w/v) BSA) + 0.1% ProClin and stored at 4 ◦C until further use.
The HAV formalin inactivated full virus preparation was immobilized according to the
manufacturers’ protocol with Mix & Go from Anteo Diagnostics (AMG Activation Kit for Multiplex
Microspheres) using coordination chemistry.
2.4. Bead-Based Multiplex Assay Procedure
All single-bead populations with immobilized antigens were combined for usage in the multiplex
assay procedure. Additionally, four internal control beads were added: (1) beads with covalently
immobilized human IgG as control for the detection system, (2) beads with goat-anti-human IgG
antibody as control for the sample addition, and (3 + 4) beads with BSA and beads with E. coli lysate as
control for unspecific binding.
Plasma samples were prediluted 1:40 in PVXC (PBS + 0.8% polyvinylpyrrolidone (PVP) + 0.5%
polyvinyl alcohol (PVA) + 0.1% casein) followed by a 1:5 dilution in sample buffer (50% (v/v)
CBS + 50% (v/v) LowCross-Buffer (Candor Bioscience GmbH, Wangen, Germany) + 1 mg/mL E. coli
lysate + 0.5 mg/mL purified glutathione S-transferase (GST)), yielding a final 1:200 dilution of the
samples. After dilution, the samples were incubated for 20 min at RT. The bead mixture was diluted in
assay buffer (CBS + 0.05% Tween 20) containing approximately 20 beads/µL per single-bead population
and distributed on a 96 well PCR plate (50 µL per well). The assay was performed in a semi-automated
fashion using the magnetic particle processor mentioned above. The beads were transferred from
the bead source plate to 50 µL of the diluted human plasma samples and incubated for 2 h at RT.
Unbound antibodies were removed by washing the beads twice with wash buffer (100 µL PBS + 0.05%
Tween 20). To detect bound human IgGs the beads were incubated for 1 h at RT with 50 µL of an
R-phycoerythrin (R-PE) labeled goat-anti-human IgG antibody (Jackson ImmunoResearch, West Grove,
PA, USA) diluted to 5 µg/mL in assay buffer. After two washing steps with 100 µL wash buffer the
beads were resuspended in 100 µL wash buffer. Measurements were performed using a Luminex
FLEXMAP 3D instrument operated with Luminex xPONENT software version 4.0 (Luminex Corp.).
Binding events were displayed as median fluorescence intensities (MFI) based on ≥50 measured beads
per bead population. Every sample had its own sample specific background. The sample specific
background was the mean of the MFI values on the BSA bead and the E. coli lysate bead, which was
subtracted from the MFI values on the antigen carrying beads of the corresponding sample.
2.5. Technical Assay Validation
The multi-pathogen assay was technically validated with respect to intra- and inter-assay precision.
Assay precision is indicated as the percentage coefficient of variation (% CV). For determination of
the intra-assay precision 20 replicates of a sample were measured on one assay plate. For calculation
of the inter-assay precision, triplicates of a sample were measured on four experimental days.
The determination of the precision was performed for the blank, a negative sample, and four
positive samples.
2.6. Cutoff Definition and Methods for Sample Classification
A cutoff was calculated for every antigen based on the reactivity in negative control sera.
In this study 15 negative sera for HAV and HBV were used, for HCV 28, for CMV and T. gondii
each 10 and for H. pylori 50 negative sera. Outliers were identified using the interquartile range
(IQR). Values were considered to be outliers when the value was below Q1 – 1.5 × IQR or above
Q3 + 1.5 × IQR. Outliers were excluded from the cutoff calculations. The cutoff value for every antigen
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was defined as the mean MFI value + 3× standard deviation. Dividing the antigen-specific MFI value
of the samples by the antigen-specific cutoff yielded the signal-to-cutoff (S/CO) values.
To classify a sample into negative, borderline or positive for HAV, HBV, CMV, T. gondii, or H. pylori
the S/CO value of one pathogen-specific antigen was considered: positive samples have a S/CO > 2,
negative samples have a S/CO < 1 and borderline samples have a S/CO value between 1 and 2.
For HAV, the antigen formalin inactivated full virus preparation was used for classification, for HBV,
the antigen HBcAg, and for CMV, T. gondii, and H. pylori, the lysate of each pathogen was used.
To classify a sample as negative, borderline, or positive for HCV, the S/CO value of all five antigens
(Core g4a, Core g1b, c22 g1a, NS3 g1a and NS3 g1b) was considered. In addition, HCV-positive
samples were classified into acute or chronic infection (method development not published so far).
The criteria for HCV status classification is shown in Table 1.
Table 1. Criteria for hepatitis C virus (HCV) status classification.
HCV Status Criteria
negative neither borderline nor positive
borderline
min. 3 antigens * with a S/CO value between 1 and 2 or exactly 2 antigens * with a
S/CO value between 1 and 2 and simultaneously the sum of the S/CO from NS3
g1a and NS3 g1b is ≥ 3.2
positive min. 3 antigens* with a S/CO > 2 or 2 antigens * with a S/CO > 2 andsimultaneously the sum of the S/CO from NS3 g1a and NS3 g1b is ≥ 3.2
positive with acute infection
sum of the S/CO values of HCV antigens * < 5808 or sum of the S/CO values of
HCV antigens * > 5808 in combination with an alanine aminotransferase (ALT)
activity > 500 IU/L.
positive with chronic infection sum of the S/CO values of HCV antigens * > 5808 and an ALT activity < 500 IU/L
* Core g4a, Core g1b, c22 g1a, NS3 g1a and NS3 g1b. S/CO: signal-to-cutoff.
Furthermore, HAV-positive samples could be distinguished into positive by vaccination or
by infection. Therefore, the reactivity of the antigens VP4-VP2, VP3, and VP1 was considered:
samples from patients with HAV infection have a S/CO > 1 on all three antigens, while samples
from vaccinated patients have two or less antigens with a S/CO > 1.
Also for HBV, a more detailed classification of the samples was possible. A HBV positive sample
could be further classified as “cleared” or “non-cleared.” Therefore, the reactivity of the antigens
HBsAg ad and HBsAg ay was considered: positive samples from cleared patients have at least one
HBsAg with a S/CO > 1. HBV-positive samples without any reactivity against HBsAg (S/CO < 1)
are considered to be non-cleared. Moreover, it was determined if HBV-negative study participants
have received a vaccination against HBV. Negative study participants being vaccinated against HBV
have at least one HBsAg with a S/CO > 1.
2.7. Statistical Analysis
To evaluate the significance of differences between two distributions, the nonparametric
Mann–Whitney U test was used (p-values). Receiver operating characteristic (ROC) curve analysis was
used to illustrate the diagnostic ability of an antigen. In a first step of the method development for the
classification of samples, a random forest algorithm was used to get an impression of the diagnostic
ability of the assay. p-Values, ROC curve analysis, and sample classification with a random forest
algorithm were used for antigen evaluation. Statistical analyses were performed using R (RStudio V
0.97, Boston, MA, USA) and WEKA V 3.6 (The University of Waikato, Hamilton, New Zealand).
3. Results
3.1. Assay Development and Performance
For the development of the bead-based multi-pathogen assay, a primary set of 64 pathogen-specific
antigens including different variants of antigens were immobilized on different beads. Plasma or serum
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samples from positive and negative donors for HAV, HBV, HCV, CMV, T. gondii, and H. pylori were
measured with the primary multi-pathogen assay. The performance of every antigen was evaluated
based on the height of the background signal and the diagnostic ability using the following approaches,
like p-values, ROC curve analysis, and sample classification with a random forest algorithm (data not
shown). Only the best-performing antigens were included in the final setup of the multi-pathogen
assay consisting of 15 antigens from the six different pathogens.
The technical validation of the 15-plex multi-pathogen assay revealed a mean intra-assay precision
of CV = 3.2 ± 1.5% and a mean inter-assay precision of CV = 8.2 ± 5.3% across all 15 antigens and
all samples.
The diagnostic ability for every pathogen in the multi-pathogen assay was assessed on the basis
of the classification results of samples from positive and negative donors for HAV, HBV, HCV, CMV,
T. gondii, and H. pylori. The classification results with the corresponding diagnostic quality criteria are
shown in Table 2. The overall diagnostic accuracy was very high for all pathogens and varied between
93.8% and 100%. For HBV, HCV, and H. pylori, a larger second sample set was also available for the
validation of the diagnostic ability (Table 3).
Table 2. Diagnostic ability of the developed multi-pathogen assay to identify selected pathogens in an
initial set of samples.
HAV HBV HCV CMV T. gondii H. pylori
classification
true positive 34 33 33 19 10 36
false positive 0 2 0 0 0 1
false negative 1 2 0 1 0 1
true negative 15 28 26 10 10 39
diagnostic accuracy (%) 98.0 93.8 100 96.7 100 97.4
sensitivity (%) 97.1 94.3 100 95.0 100 97.3
specificity (%) 100 93.3 100 100 100 97.5
positive predictive value (%) 100 94.3 100 100 100 97.3
negative predictive value (%) 93.8 93.3 100 90.9 100 97.5
HAV: hepatitis A virus; HBV: hepatitis B virus; HCV: hepatitis C virus; CMV: cytomegalovirus.
Table 3. Diagnostic ability of the developed multi-pathogen assay to identify selected pathogens in a
validation set of samples.
HBV HCV H. pylori
classification
true positive 86 108 365
false positive 3 1 35
false negative 6 0 12
true negative 139 90 213
diagnostic accuracy (%) 96.2 99.5 92.5
sensitivity (%) 93.5 100 96.8
specificity (%) 97.9 98.9 85.9
positive predictive value (%) 96.6 99.1 91.3
negative predictive value (%) 95.9 100 94.7
HAV and HBV infections are vaccine-preventable diseases. Thus, another aim of the
multi-pathogen assay was to assess if the blood donors were vaccinated for HAV and/or HBV.
A positive HAV test result is caused by vaccination or by natural infection. For further classification
of HAV positive samples the reactivity against the antigens VP4-VP2, VP3, and VP1 was considered.
It could be observed that only samples from patients with an HAV infection had a reactivity (S/CO > 1)
on all these three single antigens (Table 4).
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Table 4. Discrimination of samples positive for HAV due to vaccination or natural infection.
HAV Status
Number of Reactive Antigens
0 1 2 3
vaccination (n = 15) 9 (60%) 5 (33.3%) 1 (6.7%) 0 (0%)
natural infection (n = 20) 0 (0%) 0 (0%) 1 (5%) 19 (95%)
The vaccine for HBV contains HBsAg, thus samples from vaccinated donors show an antibody
reactivity against HBsAg, but no antibody reactivity against HBcAg. In the multi-pathogen assay two
variants of the HBsAg were used, one from serotype ad and the other from serotype ay. Samples from
donors with and without vaccination against HBV were analyzed with the multi-pathogen assay and
results for the HBsAg variants were compared (Table 5). Whereas HBsAg ad shows a higher sensitivity,
HBsAg ay possesses a higher specificity.
Table 5. Identification of samples with and without vaccination against hepatitis B virus (HBV).
HBsAg ad HBsAg ay
classification
true positive 29 26
false positive 1 0
false negative 1 4
true negative 14 15
diagnostic accuracy (%) 95.6 91.1
sensitivity (%) 96.7 86.7
specificity (%) 93.3 100
positive predictive value (%) 96.7 100
negative predictive value (%) 93.3 78.9
3.2. Analysis of an Influenza Vaccination Study
The multi-pathogen assay was used to screen samples from an influenza vaccination study
consisting of 34 participants. For every participant, there was a sample before and several samples
after receiving the influenza vaccine Fluad. The screening results with the multi-pathogen assay were
analyzed for every sample. Samples were classified as positive, negative or borderline for the six
pathogens, HAV positive samples were further classified as positive due to vaccination or natural
infection, and HBV negative samples were checked for HBV vaccination. It has to be noted that
antibodies against HBsAg can also occur in samples of donors with antibody reactivity against HBcAg.
If this is the case, it is very likely that a former infection with HBV has been cleared by the immune
system. Therefore, samples, which have been classified as HBV positive, were further classified in
“cleared” (positive with anti-HBs) or “non-cleared” (positive without anti-HBs). Also, for HCV-positive
samples, a further classification of the infection status into “acute” or “chronic” was conducted. Having
more than one sample per participant made it complicated to have a consistent classification for a
certain pathogen. If the samples from the different time points yielded unequal classification results,
a participant was classified as “ambiguous” for the corresponding pathogen. Results of the pilot
influenza vaccination study are shown in Table 6.
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Table 6. Results of the influenza vaccination study.
Pathogen Classification
Study Participants





positive by vaccination 21 84.0





positive and cleared 2 66.7






acute infection 0 0













Positive test results were most commonly received for HAV (73.5%), followed by CMV (70.6%),
T. gondii (67.6%), and H. pylori (32.4%). Nearly all HAV-positive patients seemed to be positive due
to vaccination (84%). Four study participants did not show consistent classification results for HAV,
and three of them showed S/CO values around 1, leading to a negative or borderline classification.
The fourth ambiguous HAV study participant showed mostly borderline classification but was once
classified as positive (S/CO = 2.2).
Only three study participants were classified as positive for HBV. Two of the three HBV
positive study participant showed S/CO values < 5 for HBcAg, but the third showed S/CO values
of around 46. This third participant did also possess high S/CO values for HBsAg ad (~840)
and HBsAg ay (~36). One of the other two positive HBV study participants did not show any antibody
reactivity against HBsAg and the other patient had S/CO values for HBsAg ay of around 3, but no
reactivity against HBsAg ad. Therefore, the two study participants, which were anti-HBs positive,
were classified as cleared, whereas the other one was non-cleared. However, two study participants
were ambiguous because the samples were classified as negative or borderline (S/CO values ~1)
for HBV. Altogether, most of the participants were negative for HBV, but 41.4% of them showed a HBV
vaccination pattern.
For HCV, most of the study participants were negative (82.4%), no one was tested positive, and six
participants were classified as ambiguous. Four participants were ambiguous because the samples
were classified as negative or borderline, but two participants showed some positive samples (Table 7).
Especially on the antigen NS3 g1a there were high S/CO values in several samples. The first study
participant was classified as negative on day 0 and 3, but positive on day 7, 21, and 70, with a peak of
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reactivity on day 21. Aside from HCV, this participant was tested positive for HAV and CMV, but the
reactivity on these antigens remained very constant (CV = 3.7% for HAV and CV = 9.7% for CMV).
The second study participant was classified as positive on day 0, 3, 7, and 21, but borderline on day 70.
With highest reactivity on day 3, a clear decline of reactivity could be seen until day 70. In addition,
this participant was tested positive for HAV as well as T. gondii, and the reactivity on these antigens
also remained very constant (CV = 3.2% for HAV and CV = 13.1% for T. gondii), as it was observed for
the first study participant.








Classification Acute or Chronic
Core g4a Core g1b c22 g1a NS3 g1a NS3 g1b
1
0 negative - 0.0 0.1 0.1 0.0 0.3
3 negative - 0.0 0.1 0.3 0.0 0.6
7 positive acute 0.0 0.1 0.0 65.6 6.8
21 positive acute 0.0 0.2 0.1 313.8 23.2
70 positive acute 0.0 0.1 0.1 43.5 4.4
2
0 positive acute 0.0 0.4 1.7 104.2 3.5
3 positive acute 0.7 0.5 1.6 121.5 4.0
7 positive acute 1.5 0.4 1.3 92.8 3.2
21 positive acute 0.1 0.3 1.0 68.6 2.5
70 borderline - 0.7 0.2 0.9 53.7 2.0
Besides the high positivity rate for CMV, three study participants could not be classified
unambiguously for CMV. The samples of these participants were classified as negative or borderline
with S/CO values of 1.24 ± 0.25, 1.15 ± 0.29 and 1.2 ± 0.6. The samples of study day 0 (first visit of the
participants) were also screened with a commercial CMV ELISA (CMV-IgG-ELISA PKS, medac GmbH,
Wedel, Germany) and the comparison with the results of our multi-pathogen assay are shown in
Figure 1. A high correlation of measurement results of the two methods was found (Spearman’s
ρ = 0.91, p < 0.0001). The same samples were classified as positive with both assays.
Figure 1. Correlation of the cytomegalovirus (CMV) results from the multi-pathogen assay and
enzyme-linked immunosorbent assays (ELISA) measurement. Samples from day 0 of the study were
used for comparison. Spearman’s ρ is 0.91 with p < 0.0001.
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However, the classification for T. gondii of one participant was ambiguous due to some samples
classified as positive and some as borderline (S/CO = 2.46 ± 0.57). Furthermore, three study
participants were ambiguous for H. pylori with S/CO values of 0.85 ± 0.49, 1.03 ± 0.19 and 4.23 ± 2.69.
In general, it was observed that even if S/CO values vary between different study participants,
the variance within the samples of one participant (% CV) is relatively low (Figure 2). As illustrated
in Figure 2a, the variance of S/CO values for HAV and CMV is lower than for T. gondii and H. pylori.
However, lowest CV values were received for HAV (mean = 8.0, standard deviation (SD) = 8.5).
Even if CV values for CMV (mean = 12.7, SD = 5.3), T. gondii (mean = 16.6, SD = 4.4), and H. pylori
(mean = 15.3, SD = 8.2) were higher, 85.5% of the study participants showed CV values <20% (Figure 2b).
Figure 2. Boxplots of S/CO values and % CV in study participants positive for HAV, CMV, T. gondii,
or H. pylori. For every study participant, 2–5 samples from different time points after influenza
vaccination were available. The mean S/CO of every participant is shown in (a) and the corresponding
calculated CV values of the participants are illustrated in (b).
4. Discussion
Here, we present a serological bead-based immunoassay for the simultaneous detection of
antibodies against six different pathogens: HAV, HBV, HCV, CMV, T. gondii, and H. pylori. CV values
obtained during technical assay validation (intra-assay CV of 3.2 ± 1.5% and inter-assay CV of
8.2 ± 5.3%) were below 15%, which is a commonly accepted range for research assays and indicate
a robust test system. Positive and negative samples for every pathogen were used to evaluate the
diagnostic ability. Overall, the multi-pathogen assay showed a very good performance in an initial
set of samples with sensitivities of 94–100% and specificities of 93–100%. Comparable results to the
initial set of samples were also achieved with the validation set of samples for HBV and HCV. Only the
specificity of the H. pylori antigen was in the validation set lower (85.9%) than in the initial set of
samples (97.5%). The sensitivity was still very high (96.8%). In the validation set of samples, the clinical
classification as positive or negative for a H. pylori infection was determined by Warthin–Starry silver
stain and not by an antibody testing against H. pylori. Therefore, a lower value for the specificity
was expected because the serological antibody measurement cannot differentiate past from present
infections. We assume that some of the patients falsely classified as positive for H. pylori have had
an infection and cleared the bacteria, so that they were no more positive by Warthin–Starry silver
stain. However, even if the specificity for H. pylori was lower in the validation set than in the initial
set of samples, the diagnostic ability is still higher compared to Michel et al. [14], who received 89%
sensitivity and 82% specificity using a multiplex H. pylori serological assay.
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However, overall our assay revealed very high concordance (>95%) with the clinical classification
of the tested samples, which is much higher in comparison to another protein microarray for
simultaneous detection of antibodies against five human hepatitis viruses by Xu et al. [15], who received
>85% concordance. Furthermore, Augustine et al. [9] also developed a multiplex immunoassay for
different environmental pathogens including HAV, T. gondii and H. pylori and they received 89%, 100%
and 87.5% accuracy respectively. We observed the same accuracy for T. gondii and a higher accuracy
for HAV (98%) and H. pylori (92.5%).
Recently, Ye et al. [16] presented a method to discriminate vaccine-induced immunity from
natural infection with HAV. They developed an ELISA based on a recombinant protein containing
six immune-dominant epitopes from the nonstructural HAV proteins. In contrast, our method used
three structural HAV proteins and a formalin inactivated full virus preparation. We observed that
all samples (100%) from donors having received an HAV vaccination and 19 of 20 samples (95%)
from patients acutely infected with HAV could be classified correctly with our method. In comparison,
Ye et al. received a sensitivity of 93.8% and a specificity of 91.0%.
Although the HBV and HCV validation samples could verify the diagnostic ability received in
the initial set of samples, in the future also validation samples for HAV, CMV, and T. gondii have to
be analyzed with the multi-pathogen assay. In addition, studies involving bigger samples sizes of
individuals vaccinated against HAV and HBV are necessary for verification of the classification criteria
used in this study. In general, often better values for sensitivity and specificity can be achieved by
measuring a higher number of samples, whereby few falsely classified samples are of less consequence
in calculated percentages. However, this is one difficulty in the clinical validation of multiplex analysis:
a suitable number of samples for all represented pathogen detections is required with an appropriate
reference classification test result. In fact, we also used antigens from hepatitis D virus (HDV), hepatitis
E virus (HEV), and Epstein–Barr virus (EBV), but did not yet have the appropriate classified samples
(positive and negative) to validate the assay for these viruses. Therefore, we could not set a cutoff,
calculate the diagnostic ability of the antigens, or use them for analysis of the serological response in
the study cohort.
The analysis of the serological response in the influenza vaccination study showed positive test
results most commonly for HAV (73.5%), which is in accordance with the seroprevalence (63.8–83.4%)
among elderly individuals in Germany [17]. In contrast to this, we received an HAV vaccination
coverage of 61.8%, which is higher than 11.9–20.6% reported by Poethko-Müller and Schmitz [18].
Also, the HBV vaccination coverage was higher in our study (41.8%) than the 9.5–16.4% reported
by Poethko-Müller and Schmitz [18]. However, the analyzed cohort here was very small (34 study
participants), and due to the fact that it was an influenza vaccination study cohort, the individuals
could have a higher likelihood to receive vaccinations.
With three study participants tested positive for anti-HBc (8.8%), we observed an only slightly
higher prevalence for HBV than the reported prevalence in Germany of 5.1% [17]. Two of the three
anti-HBc positive study participants were also positive for anti-HBs and therefore classified as cleared.
The other one was anti-HBs negative and classified as non-cleared, but due to very low S/CO values
on HBcAg it could be possible that HBV clearance occurred a very long time ago, so that the anti-HBs
titer declined below the detection limit of the assay.
In our study, no participant was unambiguously classified as HCV-positive, which conforms
to the very low prevalence of 0.3% in Germany [17]. Nevertheless, two participants showed some
positive longitudinal samples for HCV with first an increase and then a decrease of S/CO values on
the antigen NS3 g1a, whereas reactivity against antigens of other pathogens remained very constant.
This observation might be caused by cross-reactivity induced by the influenza vaccination. Based on
the HCV reactivity profile also an acute infection with HCV followed by a clearance of the virus is
possible, but due to low prevalence of HCV in Germany this explanation is not very likely.
Besides high HAV seropositivity, we also observed a high number of seropositive study
participants for CMV (70.6%), which is in accordance with the seroprevalence >70% in German
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individuals aged >60 years as reported by Lübeck et al. [19]. Other studies often investigate younger
age groups, explaining why lower seroprevalence is observed, e.g., 27% in children aged 1–17 years [20],
42% in donors aged 20–40 years [21], or 42% in females aged <45 years [22]. In addition, the comparison
of the multi-pathogen assay with a commercial CMV ELISA showed 100% concordance of the samples
being tested positive for CMV. However, our observed result for the seroprevalence of T. gondii at 67.6%
is comparable to other studies reporting >55% in donors older than 45 years [23] or 77% in German
adults aged 70–79 years [24]. Furthermore, 32.4% of the participants in our study cohort showed
antibodies against H. pylori, which is in accordance with previous investigations with 28.9% [25]
or ~40% seropositivity [26] in comparable age groups.
Even if signals on the antigens varied between the different participants, the variance within the
longitudinal samples of one participant was relatively low. Nevertheless, some study participants
could not be classified unambiguously for some pathogens because S/CO values of the corresponding
antigen fluctuated around the cutoff. In these cases, the low variance can still cause a misclassification
of the samples. However, antibody titers in tested persons are not always static and can change
over time.
In total, the presented serological bead-based immunoassay for the simultaneous detection
of antibodies against six different pathogens is robust, sensitive, specific, and a suitable tool
for epidemiological studies. It can serve to simultaneously investigate seroprevalences for
several pathogens. By screening samples of a patient from different time points, changes in the
seropositivity against different pathogens can be monitored, e.g., before and after vaccination or
infection. The integration of antigens from other pathogens would make another application of the
multi-pathogen serological assay possible, e.g., screening of pregnant women for antibodies against
the TORCH pathogens, as it is known that infections with these pathogens during pregnancy can cause
severe outcomes to their fetus and newborn infants. However, one of the major challenging parts in
the development of a multi-pathogen serology test is the availability of respective validation samples.
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